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Abstract
Laparoscopic cholecystectomy (LC) is one of the most common surgical procedures 
performed globally but continues to carry to an unacceptably high risk of iatrogenic 
bile duct injury (BDI). In recent years several centres have proposed Near Infrared 
Fluorescent Cholangiography (NIRFC) with Indocyanine Green (ICG) as a potential 
method of dynamic intraoperative extra hepatic bile duct mapping. We provide 
an overview of the current problem of BDI during laparoscopic cholecystectomy 
including the incidence, aetiology and medico legal ramifications. We also provide 
a short summary of the enduring argument for and against routine intraoperative 
cholangiogram (IOC) and we discuss the new technology of NIRFC with ICG in detail. 
We provide an informative summary of the small number of highly heterogeneous 
clinical trials of NIRFC with ICG currently available and briefly discuss limitations of 
the technology.
a potential method of dynamic intraoperative extra hepatic bile duct mapping. ICG is exclusively excreted in the bile after intravenous administration. It rapidly accumulates in the extra hepatic biliary anatomy, which can be visualized with several of the commercially available Near Infrared laparoscopes on the market. NIRFC is convenient to use and could potentially negate the radiation dose and rates of cystic duct injury associated with standard Intraoperative Cholangiogram (IOC). However, data is limited; the published studies are all small, with highly variable methodology, outcome measures and interpretation of results, 
this is insufficient for a systematic review at the current time. 
The principles of fluorescence 
A fluorophore is defined as a substance capable of absorbing 
and emitting light energy. In the simplest terms, fluorescence is a three-step process of excitation, “relaxation” and emission. Fluorophores exist in a low energy unexcited “ground state” until excited by light of an appropriate wavelength. Once irradiated 
to the high energy state the fluorophore rapidly start to relax partially dissipating the absorbed energy as vibration or heat 
energy. The partially relaxed fluorophore then enters the 
emission phase of fluorescence, releasing the photon of energy 
as a detectable fluorescent signal of a longer wavelength. Unless, “photo bleached”, irreversible structural damage from high intensity light excitation, or quenched by molecular interaction 
ABBREVIATIONS BDI: Bile Duct Injury; DLC: Delayed Laparoscopic Cholecystectomy; FL: Fluorescent Light; HCC: Hepatocellular Carcinoma; IALC: Index Admission Laparoscopic Cholecystectomy; ICG: Indocyanine Green; ICGR-15: Indocyanine Green Retention 
Rate at 15 min; IOUS: Intraoperative Ultrasound; IV: Intravenous; LC: Laparoscopic Cholecystectomy; NICE: National Institute for Health and Care Excellence; NIR: Near Infrared; NIRFC: Near Infrared Fluorescent Cholangiography; OR: Odds Ratio; RCT: Randomized Controlled Trial; RR: Relative Risk; WL: White Light
INTRODUCTIONLaparoscopic cholecystectomy (LC) is one of the most common surgical procedures performed globally, with over 
66,000 cases are performed per year in the UK alone. Despite the prevalence of LC, it continues to carry to an unacceptably high risk of iatrogenic bile duct injury (BDI). The cause of BDI is multifactorial, combining a lack technical skill and a sustained perception error from the operating surgeon. Proponents of intraoperative cholangiogram argue cannulation of the cystic 
duct and fluorescent screening with radiopaque contrast media reduces the incidence of BDI but this is debatable and has not been conclusively proved by the current evidence base. In recent years several centers have proposed Near Infrared Fluorescent Cholangiography (NIRFC) with Indocyanine Green (ICG) as 
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in the microenvironment, a fluorophore can be repeatedly 
excited for sustained detection. It is these essential properties of 
fluorophores that allows differentiation between absorbed and 
emitted light and facilitates the multiple diagnostic utilities of 
fluorophores including perfusion assessment, tumor localization 
and bile duct mapping [1,2]. 
Indocyanine green (ICG)
Indocyanine Green (ICG) is a hydrophilic tricarbocyanine 
dye with fluorescent properties. It was developed by Eastman 
Kodak® as a sensitising agent in photograph development in 
the early 1950s and approved for clinical applications by US 
Food and Drug Authority (FDA) soon after. Early experimental 
applications of ICG mainly focused on dilutional methods of 
assessing cardiac perfusion and retinal angiography [3-5]. ICG is 
safe, with very few adverse reactions reported. Its attractiveness 
as a fluorescent imaging agent relates to its ready availability, 
stability, low toxicity and intravascular confinement properties. 
Once injected intravenously it rapidly and fully binds to serum 
lipoproteins complexes and plasma proteins [5]. ICG has a very 
broad optical window, overlapping the edge of the visible light 
and Near Infrared (NIR) region of the electromagnetic spectrum. 
The absorption spectrum of ICG is quoted between 695 and 
815nm [5-7] with ICG monomers peaking at a lower wavelength 
than ICG oligomers and albumin bound ICG [5,6,8]. The same 
is true for the emission properties of ICG with a variable peak 
emission between 780 and 845nm [5 -7,9,10]. 
ICG is exclusively excreted in bile and does not undergo any 
forms of intrahepatic conjugation, metabolism or enterohepatic 
circulation [4,7]. ICG extraction and biliary excretion is reliant 
on energy depend trans membrane carrier proteins and it has a 
biphasic eliminate profile [4,11]. The accepted pharmacokinetics 
of ICG is based in part, upon the early animal studies of Wheeler 
[12] and Ketterer [13] and Cherrick’s [7] human studies from 
the same era. ICG is detectable in the bile 15 minutes after 
administration but concentrations do not peak until two hours 
later. In the canine model, all ICG was recovered within five 
hours but in Cherrick’s human population levels remained high 
at trial termination seven hours’ post administration indicating a 
possible longer elimination profile. 
ICG shows almost complete intravascular confinement in 
healthy tissue but delayed washout of up to 72 hours in diseased 
and malignant tissue [12]. Several factors adversely affect 
the clearance of ICG. Bilirubin is a competitive inhibitor of ICG 
uptake by hepatocytes, as is hypo-perfusion and altered hepatic 
microcirculation. In clinical practice, severe liver disease with 
severely reduced hepatocyte function, raised serum bilirubin and 
low albumin states and hypotension all adversely affect ICG and 
clearance rates. Conversely, calorific restriction increases the 
rate ICG hepatic clearance [5,13]. 
Clinical applications of ICG
Since the discovery of ICG, it has been used for a myriad of 
clinical applications. The majority have utilized the spectral and 
intravascular confinement properties of ICG for angiographic 
studies. At the 800nm wavelength, ICG shows peak absorption 
and this conveniently overlaps with the exact point whereby the 
optical density of oxygenated hemoglobin is comparable to that 
of deoxygenated hemoglobin, facilitating methods of NIR imaging 
in all three fluid mediums, bloods, plasma and serum [14]. ICG is 
also favoured for fluorescent guided surgery because the tissue 
penetrance is believed to reach up to 10mm in the correct setting. 
There is a wealth of publications describing applications 
of ICG in surgical practice; we will therefore focus primarily 
on laparoscopic cholecystectomy and briefly on hepatobiliary 
surgery only. An accepted application of ICG is retention testing 
(ICGR-15), as part of functional hepatocyte assessment prior 
to hepatic resection surgery [15]. The serum concentration of 
ICG 15 minutes after intravenous administration can act as an 
accurate surrogate marker of both hepatocyte volume, function 
and blood flow [16,17]. 
Recently, ICG with NIR technology has moved in to the 
operating theatre and has been applied as a dynamic imaging 
modality for benign and malignant pathologies in both open 
and laparoscopic surgery. ICG guided navigation in laparoscopic 
liver resection surgery is of particular interest to hepatobiliary 
surgeons. The hope is it will compensate, at least in part, for the 
lack of tactile feedback available in minimally invasive surgery. 
First trialed by Ishiwara [18], ICG is has proved highly valuable 
in Hepatocellular Carcinoma (HCC) tumour resection, in part 
because of its convenient dosing regimen. HCC localization can 
utilize the residual ICG from preoperative ICGR-15 functional 
reserve assessments and possibly the leaky basement membrane 
of tumour capillaries. By administering ICG between three and 28 
days prior to surgery groups were able to delineate all tumours 
within 5mm of the liver capsule and visualize multiple tumours 
invisible on white light inspection alone. ICG has a HCC sensitivity 
of 96% [19], produced uniform fluorescence in all lesions and 
was felt to aide intra operative decision making [20]. 
Liver metastases are common in the natural history of many 
cancers, especially colorectal cancer and must be resected if 
any attempt at long-term survival is to be made. The natural 
progression for ICG guided NIR surgery was to the field of liver 
metastases resection. HCC tumours show a characteristic uniform 
fluorescence with ICG, whereas colorectal liver metastases show 
ring enhancement with retention of the fluorophore in the 
tumour stromal and normal liver tissue junction [21]. Kudo’s [20] 
trial of NIR Fluorescence in colorectal liver metastases resection 
yielded a sensitivity of 69% (detecting 11 out of 16 lesions). 
Cholecystectomy
Cholecystectomy is a common procedure, with around 66,660 
cases performed each year in the United Kingdom. Of these, only 
around 5,000 are performed via the traditional open approach 
[22]. Laparoscopic cholecystectomy (LC) surgery was developed 
in the late 1980s and entered into standard surgical practice in 
the early 1990s. Initially, minimally invasive LC took on average, 
3 hours to complete and had a conversion to open rate of around 
15% [23,24]. Until relatively recently, acute cholecystitis and 
gallstone induced pancreatitis were a contra-indication to LC. 
Early adopters of emergency LC in acute cholecystitis reported 
the procedure feasible but with high rates of morbidity, namely 
high intra-operative blood loss and BDI incidence in excess of 
5% [25]. Many centers therefore continued to endorse open 
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cholecystectomy or Delayed Laparoscopic Cholecystectomy 
(DLC) for this patient group.
Emergency or “index admission” LC (IALC) for acute 
cholecystitis is now the gold standard treatment and 
recommended by NICE [22]. Multiple comparative studies have 
confirmed IALC as cost efficient; £4,570 compared to £4,720 
for DLC [26] and dismissed concerns around higher rate of 
BDI and open conversion [27] (Figure 1). Importantly, there is 
marked patient morbidity in the delayed group with almost 
20% of patients waiting for a DLC representing in the interim 
[28]. Despite this, only 54.8% of patients presenting with acute 
cholecystitis to UK hospitals receive an IALC and the figure varies 
widely between UK hospitals [29]. IALC is technically challenging 
and an adjunct to facilitate dynamic intraoperative bile duct 
mapping would be of great benefit to laparoscopic surgeons 
performing these operations. 
Bile duct injury (BDI)
The most feared and serious complication of laparoscopic or 
open cholecystectomy is a bile duct injury (BDI). The implications 
can be catastrophic, with significant mortality and morbidity 
for the patient and several medico-legal ramifications for the 
surgeon and hospital involved. Many years after the BDI patients 
can continue to suffer physical and psychological complications 
negatively affecting their quality of life (QoL). The impact of BDI 
on overall psychological wellness can be severe; BDI patients are 
“38 times more likely to have a reduced mental health related 
quality of life” score compared to uneventful LC patients [30] and 
self-report reduced QOL for many years after the injury [31]. 
The peak of open cholecystectomy extended from the 1970s 
up to the introduction of LC in the late 1980s. During this period 
the overall BDI rate was only 0.2% to 0.32% [32,33]. Since the 
introduction of LC, the incidence of iatrogenic BDI during LC has 
varied greatly in the literature. Earlier case series encompassing 
the LC “learning curve” period, quote significantly higher rates 
than more recent series from experienced hepatobiliary centers. 
The largest early US series retrospectively analyzing 
Figure 1 Intraoperative assessment of biliary anatomy with NIRFC after partial dissection of Calot’s triangle using the Novadaq™ Pinpoint 
Endoscopic Fluorescence Imaging System. Courtesy of G Armstrong & G Too good from St James’ University Hospital, Leeds (unpublished).
Figure 2 Intraoperative assessment of biliary anatomy with NIRFC after partial dissection of Calot’s triangle. Imaging obtained using the Novadaq™ 
Pinpoint Endoscopic Fluorescence Imaging System in Color-Segmented Fluorescence mode (CSF) a qualitative colour mapping system unique to the 
Novadaq Pinpoint System. Courtesy of G Armstrong & G Toogood from St James’ University Hospital, Leeds (unpublished).
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1,570,361 LCs performed between 1992 and 1999 found an 
overall incidence of BDI of 0.5% [34]. Strasberg’s [33] review of 
BDI during LC published in 1995 also estimates the incidence at 
0.52%. In the early years of BDI after LC 26% of patients who 
sustained a BDI died within one year of the event, compared to 
only 6.6% of the uncomplicated group. Even when considering 
independent risk factors the adjusted hazard ratio (HR) for 
mortality was 2.79 for the BDI cohort [34]. Large European 
studies from the same period report similar rates of BDI, Italy 
0.42% [35], Sweden 0.40% [36], and Switzerland 0.3% [37]. 
Iatrogenic BDI should be considered preventable. Multiple 
mechanisms and errors contribute to the occurrence of intra-
operative BDI. It remains debatable to what extent lack of 
technical skill, perception error, or combinations of these factors 
are the key underlying cause of BDI. Misidentification of the 
cystic duct is a recurring theme in retrospective analysis of BDI 
[33]. Way et al., estimate just 3% of BDI are due to a true lack 
of technical ability [38]. They analyzed 252 BDI cases, regardless 
of the extent and grade of BDI sustained; the underlying cause 
in most cases was the surgeon mistaking an extra hepatic duct 
for the cystic duct. However, previous studies attribute far more 
blame to the technical skill of the surgeon. Nuzzo et al., attribute 
“improper use of monopolar coagulation” and an inability to 
achieve early haemostasis as the primary mechanism of BDI in 
nearly 20% of reported cases [35]. 
The safety of LC has dramatically improved since the early 
days of minimally invasive surgery. UK centers that limit LC 
surgery to consultants who have declared an interest in upper 
gastrointestinal surgery and/or minimally invasive hepatobiliary 
surgery report enviable rates of open conversion and BDI during 
LC, 3.0-3.8% and 0.1% respectively [39-41]. High volume 
American centers also report a BDI incidence of around 0.08% 
[42]. 
Aside from the mortality and morbidity associated with BDI, 
there is also a significant medico-legal burden for the surgeon and 
hospital trust involved. In our litigious society patients are now 
likely to bring successful legal cases against a trust when they 
are the victim of any perceived avoidable compilation or medical 
negligence. Between 1995 and 2009 the NHS Litigation Authority 
(NHSLA) settled 303 cases emanating from LC surgery, of these, 
179 related to BDI. BDI legal cases had the highest success rate 
(77.9%) of all LC related complications and commanded one of 
the highest average pay-outs at £114,324 per case [63]. In the 
United States, the average award for LC related clinical negligence 
is four times higher than in the UK [64].
The management of the BDI is also vitally important to the 
likelihood of ligation being brought against a surgeon and the 
case being upheld. Roy’s review of NHSLA BDI cases between 
2000 and 2005 found “only half of claims for injuries that had 
been recognized promptly were successful”, compared to 90% of 
cases recognised late in the clinical course [62]. In the Netherland 
patients diagnosed with BDI more than 7 days after LC received 
on average 2.4 times higher pay-out from their ligation case than 
those diagnosed within one week [58], in the UK, this figure is 
roughly 3.6 times higher [62].
Intra-operative cholangiogram (IOC)
Since the introduction of LC multiple strategies to reduce BDI 
have been proposed and Intra-operative cholangiogram (IOC) 
is one of the most accepted. The advantage of IOC is that it can 
visualize both the intra and extra hepatic biliary anatomy, the 
presence of any ductal cholelithiasis and the flow of contrast in to 
the duodenum can be observed. However, IOC can be problematic 
and time-consuming to perform, whilst the catheterization 
process risks injury to the bile ducts. The intervention also 
carries a radiation dose both to the patient and the operating 
theatre staff. The most common reason for conducting an IOC 
is to exclude choleduocholithiasis, but Jamal et al. [43], meta-
analysis of IOC yielded a pooled sensitivity and specificity of 87% 
and 98% for this purpose. 
Proponents of IOC argue it improves outcomes, reduces BDI 
and aides intraoperative decision making processes, a viewpoint 
not held by all laparoscopic and hepatobiliary surgeons. In the 
1990s prior to the “critical view of safety” era as proposed by 
Strasberg et al., there was a flurry of publications advocating 
routine IOC. Flum’s [44] retrospective review of over one and 
a half million LCs performed during 1992 and 1999 found 
regardless of patient and surgeon factors the relative risk of BDI 
was higher (RR 1.71) when IOC was omitted. Whilst, Fletcher et 
al. [45], review of BDI in Western Australia from introduction 
up until 1994 demonstrated the greatest protective effect of 
IOC in complex biliary pathology, reducing the incidence of BDI 
from 16.9 to 2.2 per 1000 for both open cholecystectomy and LC. 
Waage et al. [36], concluded IOC reduced the incidence of BDI by 
34% (OR, 0.66; 95% CI, 0.54-0.79) in Sweden between 1987 and 
2001. This early period of LC surgery was largely experimental 
without consensus on timing or indication for LC. It is noteworthy, 
many centres viewed complex and acute biliary disease as a 
contraindication to minimally invasive surgery, limiting access to 
and experience in emergency LC for the majority of surgeons at 
this time.
Twenty-four percent of laparoscopic surgeons in the UK 
and about a third in the United States perform routine IOC with 
every LC [46,47]. In the Netherlands where surgeons adhere to a 
laparoscopic cholecystectomy protocol incorporating the critical 
view of safety, only 2.6% perform routine IOC [48]. Preoperative 
deranged liver function tests and the clinical presentation of 
cholangitis are independent risk factors for choleduocholithiasis 
[49]. Therefore, many surgeons use selective IOC when 
laboratory, radiological or intraoperative findings raise suspicion 
of intraductal pathology such as stones. IOC significantly increases 
operative duration [50], the risk of postoperative biliary infection 
and has an increased financial burden. 
It is argued that IOC only increases intraoperative detection 
but does not reduce the actual incidence of BDI. Extra hepatic bile 
duct injuries are often missed by the operating surgeon. Just 18% 
- 32% [51-55] of BDIs are recognised intra-operatively, and an 
alarmingly high proportion is not recognised until after discharge 
from hospital [52]. Ludwig et al. [53], report routine IOC both 
reduced the incidence of and increased the rate of intra-operative 
BDI identification from 0.43% to 0.21% and from 44.5% to 87% 
respectively when compared to selective IOC. At casual glance, 
Sheffield et al. [56], concur with Ludwig et al. [44,53,54], and 
with earlier published data, reporting a reduction in BDI with 
IOC from 0.36% to 0.21% between 2000 and 2009. However, 
after adjustment for immeasurable cofounders and subjecting 
the data to more rigorous statistical analysis the difference in 
Central
Bringing Excellence in Open Access


Armstrong et al. (2017)
Email: 
J Surg Transplant Sci 5(2): 1051 (2017) 5/3
outcomes when using routine IOC was not statically significant 
(p=0.31). Khan et al. [50], in a RCT of OTC using identification 
of CBD stones as the primary endpoint only, argued routine IOC 
did not reduce BDI and was not clinically indicated. Failure to 
include biliary anatomy mapping and bile duct injury as primary 
endpoints somewhat limits the validity of their small RCT with 
less than 100 patients per arm in a single centre. Ragulin-Coyle’s 
[47] retrospective review of IOC in LC between 2004 and 2009, 
after the adoption of safe best practice steps in LC including the 
critical view of safety in many centers, found no difference in 
rates of BDI between experienced surgeons who routinely use 
IOC and those who selectively apply it. 
Near infrared fluorescent cholangiography with ICG 
The stubbornly high rates of BDI, associated morbidity, 
financial ramification and difficulties associated with performing 
IOC during LC makes Near Infrared Fluorescent Cholangiography 
(NIRFC) with ICG an extremely promising potential adjuvant 
to minimal invasive hepatobiliary surgery. The potential to 
delineate the extra hepatic biliary anatomy may aid surgeon 
structure visualization and it is hoped may reduce the rate of 
serious BDI. Some proponents of the new technology believe, 
it many even negate the need for traditional intra-operative 
cholangiogram with radio-opaque contrast media in certain 
settings. The technique is simple, patients receive a preoperative 
dose of ICG and the LC surgery is performed with a dedicated 
NIR laparoscope. The ICG accumulates in the bile ducts to allow 
dynamic real time NIRFC. 
Various teams have performed standard laparoscopic, 
single incision and robotic cholecystectomy with NIRFC and 
ICG (Table 1). However, there is no consensus on dose, timing 
of administration or endpoint measures. The small sample 
sizes and differing methods used mean there is a distinct 
lack of comparative data on the emerging field of NIRFC and 
insufficient data for a systematic review of the literature at this 
time. Figueiredo et al. [57], explored NIRFC in a mouse model 
and concluded the peak intraoperative signal to noise ratio was 
achieved 25 minutes after intravenous administration. The first 
human application of ICG guided LC was reported by Ishizawa 
et al., in 2009 using a prototype NIR device [58]. They deemed 
the administration of a single intravenous dose of 2.5mg ICG two 
hours prior to surgery a success, reporting ease of visualization 
of the cystic duct (CD) and the common hepatic duct (CHD) with 
the technique. 
A small number of non-randomized prospective NIRFC trials 
have followed, using a combination of commercially available and 
prototype NIR laparoscopic devices. By far, a single preoperative 
intravenous bolus of 2.5mg of ICG is the most popular dose; every 
published trial except Boni et al. [59], who used 0.4mg/kg and 
Zroback et al. [60], who used 3.75mg, has employed this dosing 
regimen. 
Recently, Zarrinpar [61] attempted to define the optimal 
dose and timing interval and refutes the almost consensus view 
of a standardized 2.5mg dose in hepatobiliary surgery. Although 
small, 37 patients in total, and including cholecystectomies and 
partial hepatectomies, there was a clear improvement in the 
visualization of important extra hepatic biliary structures with 
higher doses of ICG administered at a longer pre-operative 
interval. Using a semi-quantitative scoring system, they suggest 
“a dose of 0.25mg/kg administered at least 45miniutes prior to 
visualization facilitates Intraoperative anatomical identification”. 
This is well within the safe adult total daily dose limit of 5mg/
kg of ICG. Indeed, with endemic levels of obesity in the Western 
world a standardized low dose feels counterintuitive. Several trial 
protocols had scope for additional doses of ICG, but these were 
rarely required owing to the prolonged fluorescence produced by 
ICG excreted in to bile. The only exception being whereby a team 
wished to delineate the vascular anatomy; in this situation, they 
gave small additional doses of ICG map the cystic and hepatic 
arteries [59]. 
The exact timing is also a contentious issue and must take in 
to consideration the noise to signal ratio created by background 
liver fluorescence. All studies were guided by the elimination 
properties of ICG and administered a dose prior to induction of 
anesthesia, however this ranged from 15 minutes to more than 
two hours prior to start of surgery time. Verbeek et al. [62], 
attempted to define the optimal dosing regimen in open hepatic 
surgery prior to application in LC. Pushing the limits of ICG 
detectable fluorescence, they proposed 10mg administered 24 
hours prior to LC as the optimal dose. They report far less liver 
background signal and therefore greater contrast between the 
liver and the common bile duct with easier surgeon visualization 
with prolonged dosing. However, in a surgical setting, where 
most LCs is performed on a day-case basis, the feasibility of 
administering intravenous ICG the day before surgery may 
be questionable. Zarrinpar [61] observed improved contrast 
between the liver, ducts and fat with prolonged dosing (3 hours) 
too, but compromised to a more achievable 45 minutes with the 
addition of a higher dose to compensate. 
A major drawback of NIRFC is its limited depth of tissue 
penetration, somewhere in the region of 5 to 10mm. In 2013 
67% of men and 57% of woman in the England were considered 
overweight or obese [63] (Figure 2). This figure continues to rise 
and is far higher than when LC was first introduced in to NHS 
surgical practice. Operating on patients with a high Body Mass 
Index (BMI) score and therefore large volumes of intraabdominal 
adipose tissue in now a common occurrence and poses its own 
set of challenges to surgical teams. Japanese and American teams 
piloting NIRFC have attempted to explore the effect of obesity 
of extra hepatic ductal visualization. Osayi et al., using an ICG 
dose of 2.5mg total in the USA could only visualize the CBD in 
64% of patients with a BMI over 35kg/m2 and in one super 
morbidly obese patient with a BMI of 63kg/m2 the CD was the 
only structure detected with NIRFC [64-69]. Other teams report 
similar difficulties with NIRFC in the overweight or obese patient 
too, including the need for extensive dissection in Calot’s triangle 
to achieve any visualization, [65] and a longer operative time 
[70-75]. Kono et al. [76], in Japan contradicts this view, “BMI had 
not predictive value for detection” of the CD and CBD confluence. 
Although it is important the median BMI was only 23.5kg/m2 in Kono’s study versus a mean 31.49kg/m2 in Osayi’s later 
publication. 
In other fields of NIRF surgery with ICG as the fluorophore, 
advanced BMI was found to adversely affected structure 
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Table 1: Summary of NIRFC with ICG cholecystectomy clinical trials published 2009 to 2016.
Author Country Year Number of patients receiving ICG Procedure dose
Pre-operative 
ICG dosing 
interval 
(1. as per 
methodology 
and 2. Achieved 
dosing interval)
Mode of 
admission
Zroback 
[63]
Canada 2016 12 Laparoscopic cholecystectomy (LC) 3.75mg
1. “pre-op”
2. n/a
Elective
Buchs [70] USA 2013 23 Robotic single site cholecystectomy 2.5mg
1. “30-45min” 
pre-op.
2. n/a
Elective
Osayi [68] USA 2015 82 LC 2.5mg
1. n/a
2. Mean 
73.8±26.4m to 
incision
Elective
Tagaya 
[73]
Japan 2009 12 8 LC 4 open 2.5mg
1. 1-2 h pre-op
2. n/a
Elective
Boni [59] Italy 2015 52 LC 0.4mg/kg
1. n/a
2. 15m prior to 
incision
(range14±9m)
Acute & 
elective
Schols[74] Netherlands 2013 15 LC 2.5mg
1. n/a
2. Mean 33m 
(range 19-67m)
To 1st 
visualisation
Elective
Daskalaki 
[69]
USA 2014 184
Robotic LC
(112 multiport & 72 single port)
2.5mg
1. 45m
2. n/a
Elective & 
acute
Spinoglio 
[75]
Italy 2013 45 Robotic single port 2.5mg
1. 45m
2. n/a
Elective
Igami [76] Japan 2016 21 Single incision LC 2.5mg
1. n/a
2. 39m±4 (to 1st 
incision)
Elective
Ishizawa 
[77]
Japan 2011 7 Single incision LC 2.5mg
1.
2. 35 – 75m prior
(to 1st 
visualisation)
Elective
Ishizawa 
[61]
Japan 2009 1 LC 2.5mg
1. 2 h “pre-
operatively”
2. n/a
Elective
Kono [71] Japan 2015 108 LC 2.5mg
1. n/a
2. Median 90m 
(range 15 -165m)
Elective & 
Acute
Ishizawa 
[78]
Japan 2010 52 LC 2.5mg
1. n/a
2. 110m mean 
(range 35 -165m) 
to 1st incision
Elective
Zarrinpar 
[64]
USA 2016 37
LC (13)
open cholecystectomy (1)
laparoscopic bile duct exploration (2)
laparoscopic partial liver resection 
(6)
open partial liver resection (11)
0.02 to 
0.25mg/
kg range
1. n/a
2. 3 groups
a)10m±3m,
b) 45m±15m
c) 3h±1h
Elective & 
acute
Abbreviations: LC: Laparoscopic Cholecystectomy; h: hour; m: minute
visualization [77,78]. To further compound the difficulties of 
using NIRFC in a population with endemic levels of obesity is 
the inflammatory process underling cholecystitis and gallstone 
pancreatitis. The characteristic development of pericholecystic 
inflammation and tissue oedema, leads to thickening of the 
gallbladder wall and inflammatory exudates in the surrounding 
tissues, which all increase the tissue density and depth between 
duct and camera detector. This is all likely to reduce the 
diagnostic yield of NIRFC in the obese and in those with the most 
severe acute biliary pathology who often demonstrate dense 
adhesions and pericholecystic inflammation. Recent experience 
at our centre has also found reduced efficacy in high BMI patients 
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and patients with acute cholecystitis. These cases are the most 
technically challenging to complete laparoscopically and would 
show greatest benefit from the adjuvant of NIFRC if it were able 
to penetrate tissue of this density consistently and show clear 
delineation of structures. 
DISCUSSION 
The consequences of BDI during laparoscopic cholecystectomy 
are catastrophic for the patient and surgeon involved. BDI must 
be considered preventable but rate remain stubbornly high even 
in the most experienced of HPB centers. The merits of routine 
IOC have been debated for nearly twenty years without any sign 
of a consensus being reached. The literature fails to support the 
argument for routine IOC and it must be remembered IOC is time 
consuming to perform, risks injury to the bile ducts and exposes 
theatre staff and patients to ionizing radiation. There is a clear 
need for an alternative method of Intraoperative extra hepatic 
bile duct mapping, a method that is dynamic, easier, quicker and 
safer to apply intraoperatively. 
NIRFC with ICG during LC surgery is an extremely promising 
adjuvant to minimally invasive surgery and may help to reduce 
the feared BDI complications associated with LC surgery. ICG 
is safe, cheap and readily accessible in most hospitals; whilst 
commercially available NIR laparoscopic systems are now 
comparable in price to standard white light models. 
Our limited experience of NIRFC in a straightforward case 
has been extremely positive. At our institution we have found 
the NIRFC technology to be a useful adjunct in elective LCs aiding 
bile duct mapping without increasing the operative length. Our 
only caution with NIRFC, is that predictions of NIRFC completing 
replacing traditional IOC may be premature, for NIRFC is unable 
in visualize the intrahepatic hepatic ducts or exclude intrahepatic 
cholelithiasis as IOC can. NIRFC is also limited in its tissue 
penetrance. With endemic levels of obesity in the Western world 
and IALC now the norm, surgeons are increasingly encountering 
difficult cases with dense pericholecystic tissue which is likely to 
challenge the depth of penetrance achieved with NIRFC. 
CONCLUSION 
NIRFC is extremely promising but still in its infancy, the 
technology needs more detailed exploration and evaluation. 
Currently, there is no consensus on the optimal dose or timing 
of ICG for NIFRC. Early series favored a single dose of 2.5mg 
whilst a weight adjusted dose is now more popular and may 
benefit an increasingly obese patient population. To truly test the 
hypothesis that NIFRC reduces BDI a large statistically powered 
international multicentre randomized control trial of NIRFC is 
required with the potential for meta-analysis a later date. 
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